|
|
|
|
|
|
|
HIGHLIGHTS FROM THE 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING |
|
|
|
|
|
Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient
|
|
| Optimal Treatment Intensity for Frontline Therapy for Advanced Urothelial Cancer: Which Regimen for Which Patient? |
| Pooja Ghatalia, MD |
| Pooja Ghatalia discussed optimizing frontline therapy for advanced urothelial cancer, highlighting enfortumab vedotin + pembrolizumab as the new preferred treatment. For patients unable to receive this combination, gemcitabine + cisplatin + nivolumab remains an alternative. The presentation emphasized the need for vigilant monitoring of treatment-related adverse events and explored the potential of induction therapy followed by maintenance pembrolizumab. |
|
|
|
|
|
| Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer |
| Matt Galsky, MD |
| Matt Galsky discussed using molecular testing, particularly ctDNA, to guide perioperative systemic therapy for urothelial cancer. He highlighted the potential of ctDNA as a biomarker for identifying which patients need treatment and who will benefit from it, noting its prognostic and predictive capabilities demonstrated in the IMvigor010 trial. |
|
|
|
|
|
| Bladder-Sparing Treatment Strategies for Localized Urothelial Cancer |
| Brent Rose, MD |
| Brent Rose highlighted the efficacy and safety of bladder-sparing strategies, particularly chemoradiotherapy, for localized urothelial cancer, emphasizing its comparable outcomes to radical cystectomy in selected patients. He also discussed emerging systemic therapies and the importance of patient selection and shared decision-making in treatment planning. |
|
|
|
|
|
|
|
|
|
|
|
Advancing Prostate Cancer Care: Treatment Approaches to Precision Medicine, Biomarker Innovations, and Equitable Access
|
|
| Practical Approach to Genetic Testing and Treatment Selection in Prostate Cancer |
| David James VanderWeele, MD, Ph.D. |
| David James VanderWeele discussed a practical approach to genetic testing and treatment selection in prostate cancer, emphasizing the importance of early somatic testing, especially in hormone-sensitive prostate cancer, due to its ability to predict treatment response and prognosis. He highlighted the significance of mutations in genes like BRCA2, which are linked to poorer prognosis but also to a better response to PARP inhibitors, and suggested prioritizing PARP inhibitors for BRCA1/2, CDK12, and PALB2 mutations. |
|
|
|
|
|
| Responsible and Equitable Biomarker Stewardship: How Do We Ensure Access to All Patients
|
| Timothy Rebbeck, Ph.D.
|
| Timothy Rebbeck highlighted the importance of responsible and equitable biomarker stewardship to ensure access to all patients and determine who benefits from genetic testing. He discussed how population-based and precision approaches can influence prevention, detection, and therapy, emphasizing that new medical interventions can exacerbate disparities, as seen in breast cancer and multiple myeloma outcomes among Black individuals.
|
|
|
|
|
|
| Molecular Imaging for Prostate Cancer: When and Which Agents |
| Delphine Chen, MD |
| Delphine Chen discussed the pivotal role of molecular imaging, particularly PSMA-PET, in prostate cancer (PCa) care. PSMA-PET has significantly enhanced PCa imaging, aiding in initial staging, detecting biochemical recurrence, and selecting patients for PSMA-targeted radioligand therapy. Dr. Chen highlighted the various FDA-approved PSMA agents and their applications across different stages of PCa. |
|
|
|
|
|
| Rapid Oral Abstract Session: Genitourinary Cancer—Kidney and Bladder |
|
| A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03) |
| Jae-Lyun Lee, MD, Ph.D. |
| Jae-Lyun Lee presented the results of the ULTIMA study at ASCO 2024, shedding light on the efficacy and safety of modified FOLFIRINOX as a first-line treatment for advanced urachal cancer. Urachal cancer is a rare malignancy with no established standard of care in the advanced setting. |
|
|
|
|
|
|
|
|
|
|
